Timing of dornase alpha inhalation does not affect the efficacy of an airway clearance regimen in adults with cystic fibrosis: A randomised crossover trial

Journal of Physiotherapy

Volumn 57, Issue 4, 2011, Pages 223-229

  Bishop, Jennifer R ^a   Erskine, Odette J ^a   Middleton, Peter G ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Airway clearance techniques; Cystic fibrosis; Dornase alpha; Lung function; Quality of life

Indexed keywords

DEOXYRIBONUCLEASE I; DNASE1 PROTEIN, HUMAN; EXPECTORANT AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DRUG ADMINISTRATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; CROSS-OVER STUDIES; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; DRUG ADMINISTRATION SCHEDULE; EXPECTORANTS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; YOUNG ADULT;

EID: 84855993810     PISSN: 18369553     EISSN: 18369561     Source Type: Journal    
DOI: 10.1016/S1836-9553(11)70052-2     Document Type: Article

References (19)

1. Standardization of spirometry: 1994 update. American Journal of Respiratory and Critical Care Medicine 1995, 152:1107-1136. American Thoracic Society.
2. Fitzgerald D.A., Hilton J., Jepson B., Smith L. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics 2005, 116:549-554.
3. Fuchs H.J., Borowitz D.S., Christiansen D.H., Morris E.M., Nash M.L., Ramsey B.W., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. New England Journal of Medicine 1994, 331:637-642.
4. Hubbard R.C., McElvaney N.G., Birrer P., Shak S., Robinson W.W., Jolley C., et al. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. New England Journal of Medicine 1992, 326:812-815.
5. Knudson R.J., Slatin R.C., Lebowitz M.D., Burrows B. The maximal expiratory flow-volume curve. Normal standards, variability, and effects of age. American Review of Respiratory Disease 1976, 113:587-600.
6. Jones A.P., Wallis C. Dornase alfa for cystic fibrosis. Cochrane Database of Systematic Reviews 2010, Issue 3. Art. No.: CD001127. DOI: 10.1002/14651858.CD001127.pub2.
7. 2 max. European Journal of Applied Physiology and Occupational Physiology 1989, 49:1-12.
8. Lieberman J. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. JAMA 1968, 205:312-313.
9. Pryor J.A., Prasad S.A. Physiotherapy techniques (Ch 5). Physiotherapy for Respiratory and Cardiac Problems 2008, Churchill Livingstone, London. 4th ed. J.A. Pryor, S.A. Prasad (Eds.).
10. Ramsey B.W., Astley S.J., Aitken M.L., Burke W., Colin A.A., Dorkin H.L., et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. American Review of Respiratory Disease 1993, 148:145-151.
11. Ryan G., Mukhopadhyay S., Singh M. Nebulised antipseudomonal antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No.: CD001021. DOI: 10.1002/14651858.CD001021.
12. Shak S., Capon D.J., Hellmiss R., Marsters S.A. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proceedings of the National Academy of Sciences USA 1990, 87:9188-9192.
13. Singh S.J., Morgan M.D., Hardman A.E., Rowe C., Bardsley P.A. Comparison of oxygen uptake during a conventional treadmill test and the shuttle walking test in chronic airflow limitation. European Respiratory Journal 1994, 7:2016-2020.
14. Smyth A.R., Walters S. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No.: CD001912. DOI: 10.1002/14651858.CD001912.
15. Southern K.W., Barker P.M., Solis-Moya A. Macrolide antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No.: CD002203. DOI: 10.1002/14651858.CD002203.pub2.
16. van der Giessen L.J., de Jongste J.C., Gosselink R., Hop W.C.J., Tiddens H.A.W.M. RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology 2007, 42:624-630.
17. van der Schans C.P., Prasad A., Main E. Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis. Cochrane Database of Systematic Reviews 2000, Issue 2. Art. No.: CD001401. DOI: 10.1002/14651858.CD001401.
18. Wark P., McDonald V.M. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No: CD001506. DOI: 10.1002/14651858.CD001506.pub3.
19. Wilson C.J., Robbins L.J., Murphy J.M., Chang A.B. Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better?.: a multi-center, randomized crossover trial. Pediatric Pulmonology 2007, 42:1110-1116.